Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients

Therapeutic Drug Monitoring

Volumn 33, Issue 6, 2011, Pages 699-704

  Lam, Herman ^a   Jeffery, John ^a   Sitar, Daniel S ^a   Aoki, Fred Y ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Immunosuppressive drugs; Oseltamivir; Pharmacokinetic interactions; Renal transplant

Indexed keywords

CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID; OSELTAMIVIR; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ANTIVIRAL AGENTS; BIOTRANSFORMATION; COHORT STUDIES; CROSS-OVER STUDIES; CYCLOSPORINE; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA, HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEURAMINIDASE; OSELTAMIVIR; TACROLIMUS; YOUNG ADULT;

EID: 84856094722     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182399448     Document Type: Article

References (19)

1. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;343:1363-1373. (Pubitemid 41362704)
2. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro64-0802. Clin Pharmacokinet. 1999;37:471-484. (Pubitemid 30032251)
3. Jefferson T, Jones M, Doshi P, Del Mar. C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review & meta-analysis. Br Med J. 2009;339:b5106.
4. Ison MG, Szakaly P, Shapira MY, et al. Oseltamivir Prophylaxis Significantly Reduces the Incidence of Seasonal Influenza Infection in Immunocompromised Patients. XI International Symposium on Respiratory and Viral Infections, Bangkok, Thailand, 19-22 February 2009.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
6. Cyclosporine Monoclonal Whole Blood Assay. Ref 9797-60. Abbott Park, IL: Abbott Laboratories; December 2001.
7. IMX Tacrolimus II Assay. Abbott Park, IL: Abbott Laboratories; November 2003.
8. Wiltshire H, Wiltshire B, Citron A, et al. Development of a highperformance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro64-0802, an anti-influenza drug, and its pro-drug, oseltamivir in human and animal plasma and urine. J Chromatogr. 2000;745:373-388. (Pubitemid 30665562)
9. Wallemacg P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit. 2009;31:139-152.
10. Rush DN, Cockfield SM, Nickerson PW, et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation. 2009;88:897-903.
11. Hill G, Cihlar T, Oo C, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Disp. 2002;30:13-19. (Pubitemid 34016935)
12. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58. (Pubitemid 46091591)
13. Snell P, Oo C, Dorr A, et al. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol. 2002;54:372-377. (Pubitemid 35334949)
14. He G, Massarella J, Aitkin M, et al. The safety and pharmacokinetics of the neuraminidase inhibitor Ro64-0796 when administered concurrently with paracetamol. Clin Microbiol Infect. 1999;5(suppl 3):150 (Abstract), 247.
15. Oo C, Barrett J, Dorr A, et al. Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin. Antimicrob Ag Chemother. 2002;46:1993-1995. (Pubitemid 34535229)
16. Morrison D, Ray S, Rayner C, et al. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One. 2007;2:e1305.
17. Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Ag Chemother. 2008;52:3013-3021.
18. Rayner CR, Chann P, Gieschke R, et al. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol. 2008;48:935-947. (Pubitemid 352009487)
19. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748-753.